Literature DB >> 20827750

Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.

Francesca Pistollato1, Elena Rampazzo, Luca Persano, Sara Abbadi, Chiara Frasson, Luca Denaro, Domenico D'Avella, David M Panchision, Alessandro Della Puppa, Renato Scienza, Giuseppe Basso.   

Abstract

Medulloblastoma (MDB) is the most common brain malignancy of childhood. It is currently thought that MDB arises from aberrantly functioning stem cells in the cerebellum that fail to maintain proper control of self-renewal. Additionally, it has been reported that MDB cells display higher endogenous Notch signaling activation, known to promote the survival and proliferation of neoplastic neural stem cells and to inhibit their differentiation. Although interaction between hypoxia-inducible factor-1α (HIF-1α) and Notch signaling is required to maintain normal neural precursors in an undifferentiated state, an interaction has not been identified in MDB. Here, we investigate whether hypoxia, through HIF-1α stabilization, modulates Notch1 signaling in primary MDB-derived cells. Our results indicate that MDB-derived precursor cells require hypoxic conditions for in vitro expansion, whereas acute exposure to 20% oxygen induces tumor cell differentiation and death through inhibition of Notch signaling. Importantly, stimulating Notch1 activation with its ligand Dll4 under hypoxic conditions leads to expansion of MDB-derived CD133(+) and nestin(+) precursors, suggesting a regulatory effect on stem cells. In contrast, MDB cells undergo neuronal differentiation when treated with γ-secretase inhibitor, which prevents Notch activation. These results suggest that hypoxia, by maintaining Notch1 in its active form, preserves MDB stem cell viability and expansion.
Copyright © 2010 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827750      PMCID: PMC3474900          DOI: 10.1002/stem.518

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  66 in total

1.  GFAP-positive progenitor cells produce neurons and oligodendrocytes throughout the CNS.

Authors:  Kristen B Casper; Ken D McCarthy
Journal:  Mol Cell Neurosci       Date:  2006-02-03       Impact factor: 4.314

2.  Hypoxia requires notch signaling to maintain the undifferentiated cell state.

Authors:  Maria V Gustafsson; Xiaowei Zheng; Teresa Pereira; Katarina Gradin; Shaobo Jin; Johan Lundkvist; Jorge L Ruas; Lorenz Poellinger; Urban Lendahl; Maria Bondesson
Journal:  Dev Cell       Date:  2005-11       Impact factor: 12.270

3.  Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1.

Authors:  O V Razorenova; A V Ivanov; A V Budanov; P M Chumakov
Journal:  Gene       Date:  2005-04-25       Impact factor: 3.688

4.  Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.

Authors:  Cassin Kimmel Williams; Ji-Liang Li; Matilde Murga; Adrian L Harris; Giovanna Tosato
Journal:  Blood       Date:  2005-10-11       Impact factor: 22.113

5.  Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.

Authors:  Xing Fan; William Matsui; Leila Khaki; Duncan Stearns; Jiong Chun; Yue-Ming Li; Charles G Eberhart
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

6.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells.

Authors:  Per Ø Sakariassen; Lars Prestegarden; Jian Wang; Kai-Ove Skaftnesmo; Rupavathana Mahesparan; Carla Molthoff; Peter Sminia; Eirik Sundlisaeter; Anjan Misra; Berit Bølge Tysnes; Martha Chekenya; Hans Peters; Gabriel Lende; Karl Henning Kalland; Anne M Øyan; Kjell Petersen; Inge Jonassen; Albert van der Kogel; Burt G Feuerstein; A Jorge A Terzis; Rolf Bjerkvig; Per Øyvind Enger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

7.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.

Authors:  Karlene Smith; Lakshman Gunaratnam; Melissa Morley; Aleksandra Franovic; Karim Mekhail; Stephen Lee
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

8.  The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.

Authors:  Andrew R Hallahan; Joel I Pritchard; Stacey Hansen; Mark Benson; Jennifer Stoeck; Beryl A Hatton; Thomas L Russell; Richard G Ellenbogen; Irwin D Bernstein; Phillip A Beachy; James M Olson
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

Review 10.  The MAP2/Tau family of microtubule-associated proteins.

Authors:  Leif Dehmelt; Shelley Halpain
Journal:  Genome Biol       Date:  2004-12-23       Impact factor: 13.583

View more
  51 in total

1.  HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway.

Authors:  L Qiang; T Wu; H-W Zhang; N Lu; R Hu; Y-J Wang; L Zhao; F-H Chen; X-T Wang; Q-D You; Q-L Guo
Journal:  Cell Death Differ       Date:  2011-08-05       Impact factor: 15.828

Review 2.  Hes1: a key role in stemness, metastasis and multidrug resistance.

Authors:  Zi-Hao Liu; Xiao-Meng Dai; Bin Du
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model.

Authors:  Jong-In Na; Joo-Young Na; Woo-Young Choi; Min-Cheol Lee; Man-Seok Park; Kang-Ho Choi; Jeong-Kil Lee; Kyung-Tae Kim; Jong-Tae Park; Hyung-Seok Kim
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

4.  Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.

Authors:  Gregory K Friedman; Blake P Moore; Li Nan; Virginia M Kelly; Tina Etminan; Catherine P Langford; Hui Xu; Xiaosi Han; James M Markert; Elizabeth A Beierle; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 12.300

Review 5.  Anti-inflammatory strategies in cartilage repair.

Authors:  Ying Zhang; Tyler Pizzute; Ming Pei
Journal:  Tissue Eng Part B Rev       Date:  2014-06-23       Impact factor: 6.389

Review 6.  Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment.

Authors:  Collin M Labak; Paul Y Wang; Rishab Arora; Maheedhara R Guda; Swapna Asuthkar; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

7.  Experimental selection of hypoxia-tolerant Drosophila melanogaster.

Authors:  Dan Zhou; Nitin Udpa; Merril Gersten; DeeAnn W Visk; Ali Bashir; Jin Xue; Kelly A Frazer; James W Posakony; Shankar Subramaniam; Vineet Bafna; Gabriel G Haddad
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 8.  The roles of hypoxia-inducible factors in regulating neural stem cells migration to glioma stem cells and determinating their fates.

Authors:  Suojun Zhang; Xiao Luo; Feng Wan; Ting Lei
Journal:  Neurochem Res       Date:  2012-09-19       Impact factor: 3.996

9.  Intra-operative 5-aminolevulinic acid (ALA)-induced fluorescence of medulloblastoma: phenotypic variability and CD133(+) expression according to different fluorescence patterns.

Authors:  Alessandro Della Puppa; Giorgio Gioffrè; Marina Paola Gardiman; Chiara Frasson; Diego Cecchin; Renato Scienza; Luca Persano
Journal:  Neurol Sci       Date:  2013-12-07       Impact factor: 3.307

10.  HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast.

Authors:  Cigdem Ercan; Jeroen F Vermeulen; Laurien Hoefnagel; Peter Bult; Petra van der Groep; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2012-09-25       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.